MA42597A - 2-amino-3-fluoro-3-(fluorométhyl)-6-méthyl-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 - Google Patents
2-amino-3-fluoro-3-(fluorométhyl)-6-méthyl-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1Info
- Publication number
- MA42597A MA42597A MA042597A MA42597A MA42597A MA 42597 A MA42597 A MA 42597A MA 042597 A MA042597 A MA 042597A MA 42597 A MA42597 A MA 42597A MA 42597 A MA42597 A MA 42597A
- Authority
- MA
- Morocco
- Prior art keywords
- tetrahydropyridines
- fluoromethyl
- fluoro
- phenyl
- amino
- Prior art date
Links
- 229940125759 BACE1 protease inhibitor Drugs 0.000 title 1
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical class F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201500465 | 2015-08-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA42597A true MA42597A (fr) | 2018-06-20 |
Family
ID=56615973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA042597A MA42597A (fr) | 2015-08-12 | 2016-08-10 | 2-amino-3-fluoro-3-(fluorométhyl)-6-méthyl-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US20180244645A1 (fr) |
| EP (1) | EP3334720A1 (fr) |
| JP (1) | JP2018531889A (fr) |
| KR (1) | KR20180033524A (fr) |
| CN (1) | CN107849011A (fr) |
| AR (1) | AR105668A1 (fr) |
| AU (1) | AU2016305275A1 (fr) |
| BR (1) | BR112017007472A2 (fr) |
| CA (1) | CA2993630A1 (fr) |
| CL (1) | CL2018000375A1 (fr) |
| CO (1) | CO2018000798A2 (fr) |
| CR (1) | CR20180077A (fr) |
| DO (1) | DOP2018000040A (fr) |
| EA (1) | EA201890256A1 (fr) |
| EC (1) | ECSP18010535A (fr) |
| HK (1) | HK1253372A1 (fr) |
| IL (1) | IL257007A (fr) |
| MA (1) | MA42597A (fr) |
| MX (1) | MX2018001699A (fr) |
| NI (1) | NI201800020A (fr) |
| PE (1) | PE20181015A1 (fr) |
| PH (1) | PH12018500268A1 (fr) |
| RU (1) | RU2018104868A (fr) |
| TN (1) | TN2018000035A1 (fr) |
| TW (1) | TW201718543A (fr) |
| WO (1) | WO2017025559A1 (fr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3458B1 (ar) | 2014-11-10 | 2020-07-05 | H Lundbeck As | 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1 |
| CR20170187A (es) | 2014-11-10 | 2018-02-01 | H Lundbeck As | 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer |
| MA40941A (fr) | 2014-11-10 | 2017-09-19 | H Lundbeck As | 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 |
| JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| TW201717948A (zh) | 2015-08-10 | 2017-06-01 | Ｈ 朗德貝克公司 | 包括給予２－胺基－３，５，５－三氟－３，４，５，６－四氫吡啶的聯合治療 |
| US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| WO2018078042A1 (fr) | 2016-10-28 | 2018-05-03 | H. Lundbeck A/S | Traitements combinés comprenant l'administration d'imidazopyrazinones |
| AU2017350473A1 (en) | 2016-10-28 | 2019-04-18 | H. Lundbeck A/S | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders |
| BR112018017058A2 (pt) * | 2016-12-21 | 2019-07-02 | H Lundbeck As | 6-amino-5-fluoro-5-(fluorometil)-2,3,4,5-tetra-hidropiridin-2-il-fenil-5-(metóxi-d3)-pirazina-2-carboxamidas e derivados fluorados do mesmo como inibidores de bace1 |
| EP3723807B1 (fr) | 2017-12-14 | 2021-10-20 | H. Lundbeck A/S | Traitements combinés comprenant l'administration de 1h-pyrazolo [4,3-b] pyridines |
| AR113926A1 (es) | 2017-12-14 | 2020-07-01 | H Lundbeck As | Derivados de 1h-pirazolo[4,3-b]piridinas |
| WO2019121840A1 (fr) | 2017-12-20 | 2019-06-27 | H. Lundbeck A/S | Pyrazolo[3,4-b]pyridines et imidazo[1,5-b]pyridazines utilisées en tant qu'inhibiteurs de pde1 |
| KR20210112968A (ko) | 2020-03-07 | 2021-09-15 | 장성환 | 양면 인쇄가 가능한 라벨 제조방법 |
| KR20230012296A (ko) | 2021-07-15 | 2023-01-26 | 장성환 | 양면 인쇄가 가능한 라벨 제조방법 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1395257A1 (fr) | 2001-06-12 | 2004-03-10 | Elan Pharmaceuticals, Inc. | Macrocycles utiles dans le traitement de la maladie d'alzheimer |
| GB0124928D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| ATE375980T1 (de) | 2002-02-12 | 2007-11-15 | Smithkline Beecham Corp | Nicotinamide und deren verwendung als p38 inhibitoren |
| AR077277A1 (es) | 2009-07-09 | 2011-08-17 | Lilly Co Eli | Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer |
| MX339640B (es) | 2010-06-09 | 2016-06-01 | Janssen Pharmaceutica Nv * | Derivados de 5, 6-dihidro-2h-[1, 4] oxazin-3-il-amina utiles como inhibidores de la beta-secretasa (bace). |
| CA2824097A1 (fr) | 2011-01-12 | 2012-07-19 | Novartis Ag | Derives d'oxazine et leur utilisation dans le traitement de troubles neurologiques |
| MY162413A (en) | 2011-01-13 | 2017-06-15 | Novartis Ag | Novel heterocyclic derivatives and their use in the treatment of neurological disorders |
| US8754075B2 (en) | 2011-04-11 | 2014-06-17 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE1 and/or BACE2 inhibitors |
| US8883779B2 (en) | 2011-04-26 | 2014-11-11 | Shinogi & Co., Ltd. | Oxazine derivatives and a pharmaceutical composition for inhibiting BACE1 containing them |
| CN103717592A (zh) | 2011-06-07 | 2014-04-09 | 霍夫曼-拉罗奇有限公司 | 作为bace1和/或bace2抑制剂的卤代-烷基-1,3噁嗪类 |
| UY34278A (es) | 2011-08-25 | 2013-04-05 | Novartis Ag | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades |
| US8338413B1 (en) | 2012-03-07 | 2012-12-25 | Novartis Ag | Oxazine derivatives and their use in the treatment of neurological disorders |
| EP2827857A4 (fr) | 2012-03-20 | 2016-03-30 | Elan Pharm Inc | Dihydro-thiazine spirocycliques et inhibiteurs de bace dihydro-oxazine et compositions et utilisations de ceux-ci |
| WO2014056816A1 (fr) | 2012-10-10 | 2014-04-17 | F. Hoffmann-La Roche Ag | Association d'un anticorps aβ et d'un inhibiteur de bace |
| EP2912035A4 (fr) | 2012-10-24 | 2016-06-15 | Shionogi & Co | Dérivés de dihydrooxazine ou d'oxazépine ayant une activité inhibitrice de bace1 |
| WO2014134341A1 (fr) | 2013-03-01 | 2014-09-04 | Amgen Inc. | Composés perfluorés 5,6-dihydro-4h-1,3-oxazine-2-amine substitués en tant qu'inhibiteurs de la bêta-sécrétase et procédés d'utilisation correspondants |
| JO3318B1 (ar) | 2013-06-18 | 2019-03-13 | Lilly Co Eli | مثبطات bace |
| KR20160115936A (ko) | 2014-02-19 | 2016-10-06 | 하. 룬드벡 아크티에셀스카브 | 알츠하이머병의 치료를 위한 bace1 저해제로서의 2-아미노-3,5,5-트리플루오로-3,4,5,6-테트라하이드로피리딘 |
| TW201623295A (zh) | 2014-04-11 | 2016-07-01 | 塩野義製藥股份有限公司 | 具有ｂａｃｅ１抑制活性之二氫噻及二氫衍生物 |
| JO3458B1 (ar) | 2014-11-10 | 2020-07-05 | H Lundbeck As | 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1 |
| CR20170187A (es) * | 2014-11-10 | 2018-02-01 | H Lundbeck As | 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer |
| MA40941A (fr) | 2014-11-10 | 2017-09-19 | H Lundbeck As | 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 |
| TW201717948A (zh) | 2015-08-10 | 2017-06-01 | Ｈ 朗德貝克公司 | 包括給予２－胺基－３，５，５－三氟－３，４，５，６－四氫吡啶的聯合治療 |
-
2016
- 2016-08-10 EP EP16748316.3A patent/EP3334720A1/fr not_active Withdrawn
- 2016-08-10 AU AU2016305275A patent/AU2016305275A1/en not_active Abandoned
- 2016-08-10 KR KR1020187004062A patent/KR20180033524A/ko not_active Withdrawn
- 2016-08-10 RU RU2018104868A patent/RU2018104868A/ru not_active Application Discontinuation
- 2016-08-10 US US15/751,765 patent/US20180244645A1/en not_active Abandoned
- 2016-08-10 US US15/233,463 patent/US10011596B2/en not_active Expired - Fee Related
- 2016-08-10 HK HK18112668.6A patent/HK1253372A1/zh unknown
- 2016-08-10 TW TW105125417A patent/TW201718543A/zh unknown
- 2016-08-10 MA MA042597A patent/MA42597A/fr unknown
- 2016-08-10 WO PCT/EP2016/069029 patent/WO2017025559A1/fr not_active Ceased
- 2016-08-10 AR ARP160102458A patent/AR105668A1/es unknown
- 2016-08-10 CR CR20180077A patent/CR20180077A/es unknown
- 2016-08-10 CN CN201680045234.5A patent/CN107849011A/zh active Pending
- 2016-08-10 MX MX2018001699A patent/MX2018001699A/es unknown
- 2016-08-10 TN TNP/2018/000035A patent/TN2018000035A1/en unknown
- 2016-08-10 CA CA2993630A patent/CA2993630A1/fr not_active Abandoned
- 2016-08-10 JP JP2018506847A patent/JP2018531889A/ja active Pending
- 2016-08-10 PE PE2018000231A patent/PE20181015A1/es not_active Application Discontinuation
- 2016-08-10 BR BR112017007472A patent/BR112017007472A2/pt not_active Application Discontinuation
- 2016-08-10 EA EA201890256A patent/EA201890256A1/ru unknown
-
2018
- 2018-01-18 IL IL257007A patent/IL257007A/en unknown
- 2018-01-26 CO CONC2018/0000798A patent/CO2018000798A2/es unknown
- 2018-02-05 PH PH12018500268A patent/PH12018500268A1/en unknown
- 2018-02-06 NI NI201800020A patent/NI201800020A/es unknown
- 2018-02-08 DO DO2018000040A patent/DOP2018000040A/es unknown
- 2018-02-09 CL CL2018000375A patent/CL2018000375A1/es unknown
- 2018-02-09 EC ECIEPI201810535A patent/ECSP18010535A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017025559A1 (fr) | 2017-02-16 |
| EP3334720A1 (fr) | 2018-06-20 |
| IL257007A (en) | 2018-03-29 |
| US20170044151A1 (en) | 2017-02-16 |
| MX2018001699A (es) | 2018-05-07 |
| PH12018500268A1 (en) | 2018-08-13 |
| RU2018104868A (ru) | 2019-09-13 |
| US10011596B2 (en) | 2018-07-03 |
| CN107849011A (zh) | 2018-03-27 |
| ECSP18010535A (es) | 2018-04-30 |
| PE20181015A1 (es) | 2018-06-26 |
| CA2993630A1 (fr) | 2017-02-16 |
| BR112017007472A2 (pt) | 2018-01-23 |
| HK1253372A1 (zh) | 2019-06-14 |
| CL2018000375A1 (es) | 2018-07-06 |
| TW201718543A (zh) | 2017-06-01 |
| EA201890256A1 (ru) | 2018-06-29 |
| JP2018531889A (ja) | 2018-11-01 |
| DOP2018000040A (es) | 2018-04-30 |
| CR20180077A (es) | 2018-04-09 |
| NI201800020A (es) | 2018-06-29 |
| CO2018000798A2 (es) | 2018-05-10 |
| KR20180033524A (ko) | 2018-04-03 |
| AU2016305275A1 (en) | 2018-02-08 |
| AR105668A1 (es) | 2017-10-25 |
| US20180244645A1 (en) | 2018-08-30 |
| TN2018000035A1 (en) | 2019-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA42597A (fr) | 2-amino-3-fluoro-3-(fluorométhyl)-6-méthyl-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 | |
| IL272407A (en) | Molecules for use in pest control, and intermediates, preparations, and related processes | |
| IL256898A (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
| MA45591A (fr) | Dérivés de 1,3-dihydroxy-phényle utiles comme immunomodulateurs | |
| LT3580220T (lt) | Aminotriazolopiridinai, kaip kinazės inhibitoriai | |
| MA41251A (fr) | Dérivés de thiéno[2,3-c]pyrrol-4-one comme inhibiteurs erk | |
| LT3371190T (lt) | Heterocikliniai junginiai, kaip pi3k-gama inhibitoriai | |
| MA43761A (fr) | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides comme inhibiteurs de la apj | |
| MA40941A (fr) | 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 | |
| EP3385302A4 (fr) | Composition polymère | |
| ZA201702797B (en) | 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors | |
| MA41977A (fr) | Imidazopyrazinones utilisées comme inhibiteurs de pde1 | |
| EP3334726A4 (fr) | Compositions de plinabuline | |
| IL252195B (en) | Molecules with use in pest control, and intermediate products, preparations and processes related to them | |
| LT3704118T (lt) | Aminoimidazopiridazinai, kaip kinazės inhibitoriai | |
| ZA201701131B (en) | Novel 2,5-substituted pyrimidines as pde4 inhibitors | |
| EP3223820A4 (fr) | Composés iminopyrimidinones condensés oxacycliques en c5-c6 utilisés comme inhibiteurs de bace, compositions et utilisation associées | |
| FR3025204B1 (fr) | Copolymeres a blocs utilisables comme fluidifiants | |
| EP3368519A4 (fr) | Nouveaux antioestrogènes hétérocycliques | |
| GB201513614D0 (en) | Compositions, compounds and methods and uses relating thereto | |
| IL262850B (en) | Prostaglandin derivative, preparations containing it and its uses | |
| EP3191447A4 (fr) | Composés de s-imino-s-oxo iminothiazine en tant qu'inhibiteurs de bace, compositions, et leur utilisation | |
| EP3274089A4 (fr) | Composition de catalyseur présulfuré | |
| EP3118227A4 (fr) | Composition de 1-octène | |
| MA42604A (fr) | 2-amino-7a-phényl-3,4,4a,5,7,7a-hexahydrofuro[3,4-b]pyridines comme inhibiteurs de bace1 |